The circle is really messy! Big Mac Pfizer may have to split?
As we all know, the US biomedical industry has entered a period of merger and acquisition. However, during this period, there are some biomedical giants who have to do the opposite. Far away, Baxter's one-two division is relished by the industry. The separated subsidiary, Baxalta, has recently achieved great success. Another biopharmaceutical giant, Shire, is bidding 30 billion yuan, hoping to put it in the bag. Coincidentally, it has recently been reported that the “big Mac†Pfizer company in the biomedical industry is also considering splitting the company into two. The company's CEO Ian Read also confirmed the news and said that the company will make a final decision on whether to split the company in the fourth quarter of 2016. At this time, Pfizer, a capital crocodile that is making waves in the capital market, is awaiting approval from the relevant departments for its $17 billion acquisition of Hospira. Read said in a conference call last week that the company has been working hard to pursue a suitable opportunity to achieve this. And Pfizer's CFO, Frank A. D'Amelio, directly pointed out that the company has spent $300 million on this, and in 2015 alone spent more than $164 million on this plan. Why does Pfizer want to "separate"? First of all, of course, the trend of highly specialized division of labor in the biomedical industry. In fact, Pfizer's current business system is divided into two parts: “innovative products†and “existing productsâ€. Through the divestiture of the company's business, it is possible to specialize in the future of the new company. Second is due to financial considerations. Earlier analysis has pointed out that in the past two years, an important reason for Pfizer's continuous industrial mergers is to reduce its own high tax rate. Once Pfizer is split into two or more small companies with different registration locations, the company will save billions of taxes in the future. However, this seemingly beautiful road is destined to be tortuous. As a biomedical giant founded in 1849, the complex relationships within the company are a major problem in Ian Read and its separation program, not to mention the fact that Pfizer has acquired many new assets through mergers and acquisitions in recent years. At the same time, some analysts believe that Pfizer will need to prepare the audited financial statements for the last three years (2014-2016) before starting the business separation plan. Therefore, Pfizer can only start this program in 2017 at the earliest. Read emphasizes that the company's premise of this plan is that the company's financial situation is sufficient to support, and Read also said that it should take into account the interests of the company's shareholders. Prior to this, Pfizer's attitude toward business separation has already begun to take shape. In 2012, the company announced that it would divest some non-core businesses. Pfizer remains an important buyer in the merger market However, if you think that this plan marks Pfizer's upcoming mergers and acquisitions in the biomedical industry, it is a big mistake. Read also stressed that the company will still put a lot of energy into the acquisition business. As everyone knows, Pfizer’s attempt to acquire AstraZeneca in the United Kingdom has caused a huge wave of growth in the biomedical industry. Recently, some analysts believe that Pfizer may also include another British pharmaceutical giant GlaxoSmithKline in the acquisition target, and even named the new company "PfizerKline". Therefore, in the future, the biomedical market will certainly hear the legend of the local Pfizer. What do the heroes see? Allergan Plc also has a split plan Not long ago, Allergan Inc. (AGN) and Actavis plc (ACT) merged to form the new Allergan Plc. There has also been news recently that Allergan Plc executives may consider splitting the company into two, separating the generic drug business into a single company. Xiao Bian said that if you look at the bio-pharmaceutical industry's points and combinations, you can only express one sentence - the circle is really chaotic! Food Grade Gelatin,Food Additives Gelatin,Bovine Gelatin Powder,Edible Gelatin Powder Hebei Haodong Biological Technology Co.,Ltd. , https://www.hdgelatin.com